Eli Lilly, Regeneron in FDA PreCheck manufacturing program
Eli Lilly and Regeneron are among the first seven companies the U.S. Food and Drug Administration selected for…
Salesforce looks to strengthen its AI platform, a positive note for J&J
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
Scientists Race to Test Treatments as Ebola Outbreak Widens
In a hastily assembled Ebola treatment center in Rwampara, Democratic Republic of Congo, Dr. Papys Lame and his…
5 things to know before the market opens Friday
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Happy Friday. Congratulations to the…
Regeneron inks drug pricing deal with Trump, will offer hearing-loss therapy for free
U.S. President Donald Trump (C) speaks during an event on advancing health care affordability in the Oval Office…
How CNBC Cures is bringing rare disease stories to a national audience
Last summer, my sister Becky approached me with an idea. She wanted my help building a platform at…
Another alliance of health care and AI signals why pharma stocks could be back
Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the…
I talked to many health CEOs out West and see big things for drug stocks
We get so caught up in the buzz and the sizzle that we forget about the steak, especially…
Johnson & Johnson halts mid-stage trial of experimental eczema drug
Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg |…